Globeflex Capital L P Takes $3.44 Million Position in DaVita Inc. $DVA

Globeflex Capital L P purchased a new stake in DaVita Inc. (NYSE:DVA) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,451 shares of the company’s stock, valued at approximately $3,438,000.

Other hedge funds have also bought and sold shares of the company. Value Investment Professionals LLC boosted its holdings in DaVita by 2.0% in the 2nd quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock valued at $556,000 after purchasing an additional 50 shares during the period. Kesler Norman & Wride LLC increased its holdings in shares of DaVita by 0.8% during the first quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock worth $1,048,000 after purchasing an additional 55 shares during the period. Gen Wealth Partners Inc raised its position in shares of DaVita by 10.0% in the fourth quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after buying an additional 80 shares in the last quarter. NewEdge Advisors LLC boosted its stake in shares of DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after buying an additional 88 shares during the period. Finally, Orion Porfolio Solutions LLC boosted its stake in shares of DaVita by 4.4% in the fourth quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock valued at $268,000 after buying an additional 99 shares during the period. 90.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

DVA has been the topic of a number of recent research reports. UBS Group raised their price objective on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Truist Financial decreased their price target on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Finally, Raymond James Financial set a $220.00 price objective on shares of DaVita in a research report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus price target of $221.75.

DaVita Price Performance

NYSE DVA opened at $174.21 on Monday. The business has a fifty day moving average price of $214.96 and a two-hundred day moving average price of $182.03. The stock has a market capitalization of $11.11 billion, a PE ratio of 14.26, a PEG ratio of 0.58 and a beta of 0.88. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. During the same quarter last year, the company posted $2.95 EPS. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 14.57 earnings per share for the current year.

Insider Transactions at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.90% of the stock is currently owned by corporate insiders.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.